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Idiopathic interstitial pneumonias are a diverse group of lung dis-
eases with varied prognoses. We hypothesized that changes in
physiologic and radiographic parameters would predict survival.
We retrospectively examined 80 patients with usual interstitial
pneumonia and 29 patients with nonspecific interstitial pneumonia.
Baseline characteristics were examined together with 6-month
change in forced vital capacity, diffusing capacity for carbon monox-
ide, and ground glass infiltrate and fibrosis on high resolution com-
puted tomography. Patients with usual interstitial pneumonia were
more likely to have a statistically significant or marginally significant
decline in lung volume, diffusing capacity for carbon monoxide,
and an increase in ground glass infiltrates (p  0.08) compared
with patients with nonspecific interstitial pneumonia. For patients
with usual interstitial pneumonia, change in forced vital capacity
was the best physiologic predictor of mortality (p  0.05). In a
multivariate Cox proportional hazards model controlling for histo-
pathologic diagnosis, gender, smoking history, baseline forced vital
capacity, and 6-month change in forced vital capacity, a decrease
in forced vital capacity remained an independent risk factor for
mortality (decrease10%; hazard ratio 2.47; 95% confidence inter-
val 1.29, 4.73; p  0.006). We conclude that a 6-month change
in forced vital capacity gives additional prognostic information to
baseline features for patients with idiopathic interstitial pneumonia.
Keywords: idiopathic pulmonary fibrosis, usual interstitial pneumonia,
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Idiopathic interstitial pneumonias are a group a diffuse paren-
chymal diseases. Usual interstitial pneumonia (UIP) and nonspe-
cific interstitial pneumonia (NSIP) comprise the majority of idio-
pathic interstitial pneumonia cases; UIP is associated with the
worst prognosis (1–5).
Recent efforts to predict prognosis for individuals with idio-
pathic interstitial pneumonia have centered on baseline physio-
logic (1, 6, 7), radiographic (7–9), and pathologic testing (1–6,
10). Little information has been published regarding the associa-
tion of serial changes in pulmonary function (11) or radiographic
features (12) and prognosis. We hypothesized that short-term
serial changes in pulmonary function and high-resolution com-
puted tomography (HRCT) would predict long-term survival in
patients with histologically defined UIP and NSIP.
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Patients with a surgical lung biopsy and serial physiologic and/or HRCT
data referred by participants in the University of Michigan Fibrotic Lung
Disease Network between October, 1989, and February, 2000, were eligi-
ble for the current study. Patients were referred due to a suspicion of
idiopathic interstitial pneumonia. Two pathologists (T.V.C., W.D.T.),
blinded to the clinical features, assigned a histologic diagnosis using
defined criteria (1, 13, 14). Only patients with UIP and NSIP formed the
study group. These patients represent a subset of previously reported
patients (1). The study was approved by the Institutional Review Board
at the University of Michigan.
Physiologic Testing and HRCT
Pulmonary function tests (PFT), including spirometry, lung volumes, and
diffusion capacity for carbon monoxide (DlCO), were performed as pre-
viously described (9). HRCT examinations were performed with 1.0- or
1.5-mm-thick sections and scored on a scale of 0–5 for ground glass opacity
(CT-alv) and interstitial opacity (CT-fib) as previously described (15).
Therapy
Patients were treated with varied treatment regimens (Table 1). The
lack of a standardized, prospective treatment regimen in the majority
of patients limited our ability to evaluate if a clear treatment effect on
survival or serial change in PFT and HRCT was present.
Statistical Analysis
Changes in PFT and HRCT scores were determined by estimating
percent change for absolute value of HRCT and PFT measurements
over a 6-month period. Measurements over a 6-month period related
to the biopsy time were used to fit a linear regression for each patient.
The fitted line from the linear regression was then used to estimate a
6-month measurement, which, together with the baseline measurement,
allowed the calculation of percent change. Percent change values over
12 months were similarly created for patients with additional data over
a 12-month period.
The date of surgical lung biopsy was used to mark the beginning
of the survival time period for each individual. Death and follow-up
times were supplemented by the use of the Social Security Death Master
File (16). Patients who had not been seen within 3 months and who
did not appear in the Social Security Death Master File were called to
confirm their vitality. Event times 3 months before the date of analysis
were censored. Three patients underwent a lung transplant; physiologic,
radiographic, and survival information was censored at the time of
transplant. Cox proportional hazards models were used to examine the
influence on survival of percent change for HRCT and PFT measure-
ments while adjusting for histopathologic diagnosis, onset of symptoms,
gender, and smoking status. The levels of more than 10% increase, be-
tween 10% decrease and 10% increase, and more than 10% decrease
were used to study percent changes of the PFT and HRCT scores. These
cutoff points were chosen a priori as they were believed to be clinically
reasonable. Survival proportions were estimated and displayed using Cox
proportional hazards models evaluated for average covariate profiles in
the study population. Characteristics for UIP versus NSIP were compared
using t tests for continuous measures and chi-square statistics and Fisher’s
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TABLE 1. TREATMENT ADMINISTERED TO 109 PATIENTS
WITH USUAL INTERSTITIAL PNEUMONIA OR NONSPECIFIC
INTERSTITIAL PNEUMONIA
Treatment Regimen UIP n (% ) NSIP n (% )
None 3 (4) 2 (7)
Prednisone alone* 25 (31) 15 (52)
Prednisone  azathioprine
or cyclophosphamide 27 (34) 4 (14)
Zileuton† 20 (25) 4 (14)
Azathioprine alone 5 (6) 4 (14)
Definition of abbreviations: NSIP  nonspecific interstitial pneumonia; UIP 
usual interstitial pneumonia.
* Thirty-one of these patients received prednisone as part of a prospective study
of high-dose steroids in idiopathic pulmonary fibrosis.
† A subset of patients were treated in a phase I/II trial comparing zileuton with
azathioprine at our institution.
exact (17) statistics for categoric measures. The potential interaction
of variables that were significantly different at baseline (UIP compared
with NSIP) and histologic diagnosis were also evaluated in multivariate
survival models. Significance of individual risk factors were tested using
Wald tests, whereas grouped risk factors were tested using likelihood




One hundred and nine patients with UIP (n  80) and NSIP
(n  29) were identified. Patients with UIP were older, had a
longer duration of symptoms, had a lower percent-predicted
total lung capacity (TLC), and more fibrosis on HRCT (Table
2). Gender distribution, CT-alv scores, and other measures of
pulmonary physiology were similar between groups.
TABLE 2. BASELINE DEMOGRAPHIC, PHYSIOLOGIC, AND RADIOLOGIC FEATURES FROM PATIENTS
WITH USUAL INTERSTITIAL PNEUMONIA AND NONSPECIFIC INTERSTITIAL PNEUMONIA
UIP NSIP t Test Wilcoxon
Characteristic (median, range) (median, range) p Value Test p Value
Sex, female/male 40/40 17/12 0.56* 0.52†
Age, yr 62 (26, 78) 53 (29, 62) 0.001 0.0004
Onset, yr 2 (0.1, 20) 0.7 (0.08, 2.5) 0.43 0.04
Weight, kg 86 (47, 125) 90 (51, 120) 0.81 0.65
Smokers, % 65  5 66  9 0.86* 1
Pack years 10 (0, 100) 20 (0, 90) 0.42 0.46
Physiologic
FVC, L 2.44 (0.97, 5.57) 2.48 (1.49, 5.27) 0.21 0.31
FVC, % predicted 67 (22, 114) 71 (44, 109) 0.26 0.22
TLC, L 4.12 (2.34, 7.68) 4.32 (2.61, 7.61) 0.14 0.21
TLC, % predicted 72 (42, 121) 82 (51, 120) 0.05 0.04
DLCO, ml/min/mm Hg 12.45 (3.42, 30.51) 12.52 (7.58, 23.6) 0.71 0.90
DLCO, % predicted 50 (17, 98) 48 (26, 80) 0.97 0.76
HRCT
Alveolar, CT-alv 1.8 (0.2, 4.2) 2.0 (0, 5) 0.78 0.60
Interstitial, CT-fib 1.9 (0.6, 3.6) 0.9 (0, 2.6)  0.0001  0.0001
Definition of abbreviations: CT-alv  high-resolution computed tomography score for ground glass; CT-fib  high-resolution com-
puted tomography score for interstitial infiltrates (see text for details); DLCO  diffusing capacity for carbon monoxide; HRCT 
high-resolution computed tomography; NSIP nonspecific interstitial pneumonia; TLC total lung capacity; UIP usual interstitial
pneumonia.
* p Values calculated by chi-squared test.
† p Values calculated by Fisher’s exact test.
Change in Serial Measurements over Time
Histologic diagnosis was significantly or marginally associated
with changes in pulmonary function and radiographic character-
istics over time (Table 3). In general, more patients with UIP had
a decline in DlCO compared with patients with NSIP, who were
more likely to show an improvement in DlCO over 6 or 12 months
of follow-up (6-month p  0.03; 12-month p  0.05). Similarly,
there was a trend for more patients with UIP to have a decline in
FVC or TLC compared with patients with NSIP (6-month p 
0.08, 0.07, respectively). Over 6 months of follow-up, a higher
percentage of patients with UIP had an increase in CT-alv com-
pared with patients with NSIP, who were more likely to show
a decrease in CT-alv (p  0.07). Observed associations between
histologic diagnosis and CT-fib percent changes over time were
not statistically significant.
Survival
The median follow-up time was 4.86 years (95% confidence
interval [CI], 4.46, 5.84); median survival was 5.81 years (95%
CI, 5.22, 7.31). Initially, models studying percent change of the
PFT and HRCT measurements over time adjusted for baseline
values were investigated for patients with UIP (Table 4). De-
creased FVC over 6 months was associated with increased mor-
tality when adjusted for baseline FVC values. Patients with a
decrease in FVC greater than 10% had a higher risk of mortality
than those with a percent change between a 10% decrease and
a 10% increase (hazard ratio 2.06; 95% CI 1.09, 3.89; p  0.03;
six month change). Patients with an improved FVC of greater
than 10% were not observed to have a significantly different
hazard of mortality than those with a moderate change in either
direction. This may reflect a lack of power as there were fewer
patients with an improvement in FVC (n  14) compared with
patients with a decline in FVC (n  24). Furthermore, patients
with a greater than 10% increase in ground glass opacity on
HRCT also had a higher risk of subsequent death (relative risk
2.88; 95% CI 1.26, 6.57; p  0.01) compared with patients with
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TABLE 3. PERCENT CHANGE OF PULMONARY FUNCTION TEST AND HIGH-RESOLUTION
COMPUTED TOMOGRAPHY SCORES OVER TIME BY HISTOLOGIC DIAGNOSIS
6 Months 12 Months
UIP n (% ) NSIP n (% ) p Value* UIP n (% ) NSIP n (% ) p Value*
FVC change, % 0.08 0.10
 10% increase 14 (19) 10 (34) 6 (10) 5 (24)
10% decrease/10% increase 37 (49) 15 (52) 21 (21) 10 (48)
 10% decrease 24 (32) 4 (14) 32 (54) 6 (29)
TLC change, % 0.07 0.14
 10% increase 9 (14) 8 (35) 9 (29) 2 (22)
10% decrease/10% increase 39 (59) 12 (52) 6 (19) 5 (56)
 10% decrease 18 (27) 3 (13) 16 (52) 2 (22)
DLCO change, % 0.03 0.05
 10% increase 15 (23) 13 (50) 5 (14) 7 (47)
10% decrease/10% increase 24 (36) 4 (15) 6 (17) 2 (13)
 10% decrease 27 (41) 9 (35) 24 (69) 6 (40)
CT-alv change, % 0.07
 10% increase 25 (42) 4 (22) NA NA
10% decrease/10% increase 22 (37) 5 (28) NA NA
 10% decrease 13 (22) 9 (50) NA NA
CT-fib change, % 0.94
 10% increase 17 (28) 6 (33) NA NA
10% decrease/10% increase 24 (40) 7 (39) NA NA
 10% decrease 19 (32) 5 (28) NA NA
Definition of abbreviations: CT-alv  HRCT score for ground glass; CT-fib  HRCT score for interstitial infiltrates (see text for
details); DLCO  diffusing capacity for carbon monoxide; HRCT  high-resolution computed tomography; NA  not available;
NSIP  nonspecific interstitial pneumonia; PFT  pulmonary function test; TLC  total lung capacity; UIP  usual interstitial
pneumonia.
* p Value represents a comparison of UIP and NSIP and was calculated using Fisher’s exact test.
a less than 10% change. Changes in CT-fib or TLC were not
significant predictors of long-term survival when adjusted for
the corresponding baseline values.
Multivariate models of PFT and HRCT changes over time,
adjusting for baseline value, histologic diagnosis, onset of symp-
toms before biopsy, smoking history, and gender were examined.
A 6-month decrease in FVC of over 10% and a UIP diagnosis
were significant predictors for reduced survival compared with
patients with NSIP or moderate increases or decreases in FVC
over time (Table 5, Figure 1). The magnitude and direction of
the hazard for the levels of FVC percent change are similar to the
unadjusted model. No significant interaction between histologic
diagnosis and demographic, physiologic, or radiographic vari-
ables was noted. Changes in TLC, DlCO, CT-alv, and CT-fib
did not contribute further information once these factors were
included in the multivariate model. Baseline A–a gradient was
not a significant predictor of survival in univariate (hazard ratio
1.0; 95% CI 0.98, 1.03; p 0.79) or multivariate analysis (hazard
ratio 1.0; 95% CI 0.97, 1.04; p  0.65). Similar results were seen
in a multivariable 12-month model, although change in FVC
was no longer statistically significant.
DISCUSSION
Previous studies have identified the histopathologic pattern as
the most important baseline factor in determining prognosis
(1–5). However, the disease course for individual patients with
either UIP or NSIP can vary greatly. We hypothesized that short-
term changes in physiologic and radiographic criteria would give
additional prognostic information to the baseline features of
patients with UIP and NSIP.
In this report of a well-characterized group of patients with
UIP or NSIP, we identify (1) that a decrease in FVC during the
initial 6 months of follow-up is the best physiologic predictor of
mortality, (2) a decrease in FVC during the initial 6 months
after surgical lung biopsy gives additional information to other
previously described predictive factors such as gender, smoking
history, and histologic subtype (UIP or NSIP), and (3) patients
with UIP are more likely to experience a decline in FVC or an
increase in ground glass on HRCT over the first 6 months after
surgical lung biopsy compared with patients with NSIP. These
data aid in defining the optimal format of follow-up for patients
with UIP or NSIP and identify the change in FVC over the first
6 months of follow-up as an important additional prognostic
factor.
Our data demonstrate that change in FVC during follow-up
is the strongest physiologic predictor of survival for patients with
UIP and NSIP. The proportion of patients with a greater than
10% decrease in FVC during follow-up was greater in patients
with UIP compared with patients with NSIP. Previous investiga-
tors have suggested that decreased FVC at baseline may identify
patients at subsequent risk of mortality (18–23). In addition,
some have suggested that a decrease in FVC of 10% or more
after 1 year can predict mortality in patients with idiopathic
pulmonary fibrosis (11). Spirometric assessment is particularly
valuable as its measurement is standardized (24) and the variabil-
ity in FVC has been well defined among normal subjects and
patients with pulmonary disease (24). Despite these standards,
previous investigators have noted variability in the physiology
of patients with idiopathic interstitial pneumonia over time (25,
26). As a result, a wide variety of thresholds for change in FVC
have been used by investigators, including changes ranging from
10 to 15% in FVC (11, 22, 27–30). Our analyses document that
a 10% decrease in FVC over a 6-month period from the time
of the surgical lung biopsy exhibited strong predictive ability in
defining long-term survival. Additional data have suggested that
an increased profusion of fibroblastic foci is associated with a
greater rate of decline in pulmonary function (10) and poorer
survival (10, 31). Our data expand these findings by demonstra-
ting that change in FVC over a short duration of follow-up (6
months) is predictive of long-term survival and that this short-
term change in FVC gives additional prognostic information to
the histopathologic classification. Our data are strengthened by
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TABLE 4. PROGNOSTIC EFFECT OF PREDICTOR WHEN IN COX MODEL ADJUSTED FOR INITIAL
VALUE OF PREDICTOR IN UNIVARIATE ANALYSES OF DATA FOR PATIENTS WITH USUAL
INTERSTITIAL PNEUMONIA
Predictor n Hazard Ratio 95% CI p Value LR p Value*
6-Month change
FVC change, % 75 0.05
 10% increase 0.89 (0.36, 2.24) 0.81
10% decrease/10% increase 1.00 REF REF
 10% decrease 2.06 (1.09, 3.89) 0.03
TLC change, % 66 0.33
 10% increase 1.51 (0.63, 3.65) 0.36
10% decrease/10% increase 1.00 REF REF
 10% decrease 1.68 (0.82, 3.44) 0.16
DLCO change, % 66 0.03
 10% increase 2.49 (1.15, 5.39) 0.02
10% decrease/10% increase 1.00 REF REF
 10% decrease 0.95 (0.44, 2.05) 0.89
CT-alv change, % 60 0.01
 10% increase 2.88 (1.26, 6.57) 0.01
10% decrease/10% increase 1.00 REF REF
 10% decrease 0.81 (0.30, 2.21) 0.68
CT-fib change, % 60 0.18
 10% increase 1.09 (0.48, 2.47) 0.84
10% decrease/10% increase 1.00 REF REF
 10% decrease 0.46 (0.18, 1.16) 0.13
12-Month change
FVC change, % 59 0.15
 10% increase 0.66 (0.15, 2.86) 0.58
10% decrease/10% increase 1.00 REF REF
 10% decrease 1.70 (0.76, 3.81) 0.20
TLC change, % 31 0.29
 10% increase 0.59 (0.09, 3.67) 0.57
10% decrease/10% increase 1.00 REF REF
 10% decrease 1.50 (0.31, 7.13) 0.61
DLCO change, % 35 0.82
 10% increase 0.62 (0.09, 4.24) 0.63
10% decrease/10% increase 1.00 REF REF
 10% decrease 0.65 (0.18, 2.43) 0.53
Definition of abbreviations: CI, confidence interval; CT-alv  high-resolution computed tomography score for ground glass;
CT-fib  high-resolution computed tomography score for interstitial infiltrates (see text for details); DLCO  diffusing capacity for
carbon monoxide; LR  likelihood ratio; REF  reference group; TLC  total lung capacity.
* p Value is from the likelihood ratio test of the addition of the levels of percent change to the model that included only the
baseline measurements.
the inclusion of a well-characterized cohort with recent confir-
mation of the histopathologic pattern. The ability to look at a
short-term change in FVC gives clinicians an additional tool to
help determine prognosis for their patients and may be useful
when making therapeutic decisions such as changing therapy or
listing patients for lung transplantation. These data also suggest
that a short-term change in FVC could be used as a surrogate
marker for long-term mortality in therapeutic trials studying
patients with UIP and NSIP. Twelve-month data were less pre-
dictive of survival; however, this is likely a consequence of a
smaller number of patients available with 12-month serial data.
Our data suggest that the change in DlCO over 6 months of
follow-up has limited prognostic value. In multivariate analyses,
short-term changes in DlCO were not found to add independent
predictive value. Although standards have been presented for
its measurement (32), the DlCO varies to a greater extent than
FVC and clinically significant changes have been believed to be
more than 20% (11, 27, 28, 33). As such, a survival advantage
was noted by one group in patients with an improved or un-
changed DlCO compared with those experiencing a decrease of
20% or more after 1 year of therapy; the concordance between
changes in FVC and DlCO was quite good (11). Importantly, our
analysis suggests that changes in FVC better predict subsequent
survival for patients with UIP and NSIP.
An increase in the semiquantitative HRCT score of CT-alv
during the 6 months after biopsy was associated with an increased
risk of mortality for patients with UIP in a model adjusting
for the baseline CT-alv value. Short-term change in the semi-
quantitative HRCT score of CT-alv or CT-fib was not an inde-
pendent predictor of survival when histologic diagnosis, sex,
onset of symptoms, and smoking history were included in the
models. Our data suggest that only minor changes occur in
HRCT over the first 6 months of follow-up and may indicate
that a semiquantitative HRCT scoring system lacks sensitivity
to detect clinically useful, short-term changes in CT-alv or CT-
fib. Previous investigators have suggested that honeycombing
on HRCT worsens over intermediate-term follow-up (12, 34–37),
whereas improvement has been suggested in limited studies of
patients with NSIP (38–40). Use of computerized methods to
quantify the amount of fibrosis and ground glass infiltrate (41, 42)
may be more sensitive to serial changes in HRCT findings but
require additional study. Additional studies are required to better
define the role of serial HRCT in the follow-up and treatment
for patients with UIP and NSIP.
In summary, we demonstrate that short-term changes in FVC
are strongly predictive of long-term survival in patients with
well-defined UIP and NSIP. Furthermore, short-term changes
in FVC give additional prognostic information to previously
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TABLE 5. COX PROPORTIONAL HAZARDS MODEL EVALUATING THE RISK OF MORTALITY FOR
PATIENTS WITH UIP AND NSIP ADJUSTING FOR HISTOLOGIC DIAGNOSIS, SEX, SMOKING
HISTORY, BASELINE FVC VALUE, AND PERCENT CHANGE OVER TIME IN FVC
Predictor Hazard Ratio 95% CI p Value LR p Value*
6-Month model
UIP diagnosis 4.94 (1.81, 13.5) 0.002
Onset 1.05 (0.97, 1.13) 0.23
Female sex 0.51 (0.25, 1.08) 0.08
Positive smoking history 0.80 (0.39, 1.65) 0.54
FVC baseline 0.74 (0.44, 1.24) 0.25
FVC change (6 mo), % 0.01
 10% increase 0.88 (0.36, 2.13) 0.77
10% decrease/10% increase 1.00 REF REF
 10% decrease 2.47 (1.29, 4.73) 0.006
12-Month model
UIP diagnosis 3.50 (1.17, 10.5) 0.03
Onset 1.03 (0.89, 1.18) 0.73
Female sex 0.47 (0.19, 1.16) 0.10
Positive smoking history 1.35 (0.58, 3.14) 0.49
FVC baseline 0.42 (0.21, 0.82) 0.01
FVC change (12 mo), % 0.02
 10% increase 0.42 (0.05, 1.39) 0.12
10% decrease/10% increase 1.00 REF REF
 10% decrease 1.72 (0.78, 3.79) 0.18
Definition of abbreviations: CI  confidence interval; LR  likelihood ratio; NSIP  nonspecific interstitial pneumonia; REF 
reference group; UIP  usual interstitial pneumonia.
* p Value is associated with the likelihood ratio test for the significance of adding the levels of FVC percent change to the Cox
survival model with the other predictive factors.
described factors such as smoking history, gender, and histopath-
ologic diagnosis. In contrast, serial changes in DlCO and HRCT
are of more limited value.
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Figure 1. Cox model–based survival estimates for patients across three
levels of FVC percent change adjusted for usual interstitial pneumonia
(UIP), onset of symptoms, female gender, and positive smoking history.
Average patient profiles for UIP, onset of symptoms, sex, and smoking
were used in the estimates. Dotted line at least 10% increase in FVC,
solid line at least 10% decrease in FVC, dashed line less than 10% increase
or decrease in FVC. p  0.01.
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